Floatz logo

Cyclophosphamide

EGFR Positive Solid Tumor

Fate TherapeuticsSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the EGFR Positive Solid Tumor cohort.

Asset / SponsorPhaseRating
Fludarabine
Fate Therapeutics
Phase 1CCC
Fate-Nk100
Fate Therapeutics
Phase 1CC
Epirubicin
Fate Therapeutics
Phase 1CC
Nivolumab
Fate Therapeutics
Phase 1CC
TRASTUZUMAB
Fate Therapeutics
Phase 1CC

View all 10 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →